Extracorporeal membrane oxygenation for tuberculosis pneumonia with empyema

Santiago Besa a,*, Álvaro J. Morales b, Patricio Salas c, Sebastián Bravo M d, Luis Garrido-Olivares a

a Department of Cardiovascular Surgery, Division of Surgery, Pontificia Universidad Católica, Santiago, Chile
b Medical School, Pontificia Universidad Católica, Santiago, Chile
c Department of Thoracic Surgery, Division of Surgery, Pontificia Universidad Católica, Santiago, Chile
d Department of Intensive Medicine, Division of Internal Medicine, Pontificia Universidad Católica, Santiago, Chile

Abstract

Acute respiratory distress syndrome (ARDS) caused by Mycobacterium Tuberculosis (TB) is a rare entity. Extracorporeal membrane oxygenation (ECMO) therapy had been used as an effective therapy for this cases, but the evidence is scarce. We present a case that took place in the middle of SARS-CoV2 pandemic. A 33-year-old female patient was admitted with a 10-day history of cough, expectoration and progressive dyspnea. SARS-CoV2 infection was ruled out. Chest X-Ray showed bilateral pleural effusion, left tension pneumothorax and tuberculous cavities in the right lung (Fig. 1). A left chest tube (CT) was installed with little improvement. Due to persistent pneumothorax and air leak, two new CTs were installed upon arrival. The pleural fluid study was compatible with empyema. Treatment with rifampicin 600 mg/day, isoniazid 300 mg/day, ethambutol 800 mg/day and pyrazinamide 1.5 g/day was initiated. The patient was transferred in this condition to our center to continue her treatment. Upon admission in our hospital, APACHE II score was 17 and PaO2/FiO2 ratio was 65. No other organ disfunction was present at that moment. Due to persistent pneumothorax and air leak, two new CTs were installed upon arrival. The pleural fluid study was compatible with empyema. On the other hand, female sex and a PaO2/FiO2 ratio lower than 108.5, APACHE II score of more than 18, the presence of multiorgan-failure and consolidation images on X-Rays are described as high mortality risk factors [3,4].

There is evidence of the successful use of extracorporeal membrane oxygenation (ECMO) in the context of influenza A (H1N1) pneumonia [6,7]. Accordingly, ECMO has been used as therapy for ARDS due to TB. However, published evidence is scarce, with only 12 cases published to our knowledge [2,8–18]. We present a case of a patient with ARDS secondary to TB in whom ECMO was used as a salvage therapy in the middle of SARS-CoV2 pandemic.

1. Introduction

Acute respiratory distress syndrome (ARDS) caused by Mycobacterium Tuberculosis (TB) is a rare entity, corresponding to 4.9 % in a cohort of patients with ARDS [1]. However, a high mortality rate (60–70 %) has been described in those who require invasive mechanical ventilation (IMV) [2,3]. The presence of hyponatremia, a PaO2/FiO2 ratio lower than 108.5, APACHE II score of more than 18, the presence of multiorgan-failure and consolidation images on X-Rays are described as high mortality risk factors [3,4].

2. Case report

A 33-year-old female, homeless, with a history of type 2 diabetes, tabaquism and no previous history of lung disease was admitted with a 10-day history of cough, expectoration and progressive dyspnea. SARS-CoV2 infection was ruled out. Chest X-Ray showed bilateral pleural effusion, left tension pneumothorax and tuberculous cavities in the right lung (Fig. 1). A left chest tube (CT) was installed with little improvement. Work-up was continued with HIV antibodies testing that was negative. GeneXpert PCR on endotracheal aspirate was positive for TB, with no resistance for rifampicin. Thus, treatment with rifampicin 600 mg/day, isoniazid 300 mg/day, ethambutol 800 mg/day and pyrazinamide 1.5 g/day was initiated. The patient was transferred in this condition to our center to continue her treatment. Upon admission in our hospital, APACHE II score was 17 and PaO2/FiO2 ratio was 65.

* Corresponding author. Department of Cardiovascular Surgery, Diagonal Paraguay 362, Santiago, 8330077, Chile.
E-mail address: sbesa@uc.cl (S. Besa).

https://doi.org/10.1016/j.rmcr.2021.101481
Received 3 March 2021; Received in revised form 30 June 2021; Accepted 23 July 2021
Available online 27 July 2021
2213-0071/© 2021 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
empyema secondary to TB. Despite CTs, she remained unstable with high dose vasoactive drugs (VAD) (norepinephrine 0.8 mcg/kg/min, epinephrine 0.05 mcg/kg/min), with refractory hypoxemia (PaO₂/FiO₂ = 60) and a lung protective strategy could not be maintained. Bronchopleural fistula hindered IMV as well. In this context, she was connected to femoro-femoral veno-arterial ECMO (VA-ECMO) given her hemodynamics. After ECMO flow initiation, an oxygen saturation of 50 % in the right upper extremity and 100 % in the left upper extremity evidenced a Harlequin Syndrome, so it was converted to veno-arteriovenous (VAV) mode adding a right internal jugular cannula (Fig. 2). She required an embolectomy of the leg 12 hours after ECMO initiation after thrombosis was found in the distal arterial perfusion line. Activated clotting time was adjusted to 200–220 seconds with no further thrombotic issues. On day 4 of VAV-ECMO, VAD were suspended and ECMO was then converted to veno-venous (VV-ECMO), maintaining the right internal jugular for oxygenated blood return and femoral venous cannula for drainage and removing arterial cannulas. Due to persistent pneumothorax a left pleural decortication and fistula repair with an intercostal muscle flap was then successfully done. After 26 days on ECMO, she was weaned from support with good lung re-expansion. A week after a tracheostomy was performed. She was weaned from ventilatory support 2 weeks later. She was discharged home with in-house rehabilitation therapy 20 weeks after admission.

3. Discussion

ARDS secondary to TB is a rare entity with high mortality [2,3]. The evidence of ECMO support in these cases is scarce and is only in the form of case reports. However, the experience had been positive, with 11/12 cases with good results [2,8–15,17,18], with the non-recovered patient being a case where TB was diagnosed post mortem [16]. Most of these cases used VV-ECMO, with VA-ECMO reserved for concomitant cardiologic involvement [15]. A novel aspect of this case is that the initial modality was VAV-ECMO because of hemodynamic compromise and the development of Harlequin Syndrome. This is a described complication of VA-ECMO, produced by a preserved or recovering heart function combined with a poor lung function, so the native desaturated cardiac output flows against the well oxygenated retrograde pumped blood. Thus, the heart and upper body receives poorly oxygenated blood. This is solved using the described VAV configuration, which combines a VV and a VA ECMO [19]. After patient hemodynamics recovered and no
support was needed, modifying to VV-ECMO was a very simple procedure given the initial VAV configuration (Fig. 2). Complications of ECMO include kidney injury requiring hemofiltration (52 %), bleeding (33 %), sepsis (26 %), hemolysis (18 %), liver failure (16 %), lower extremity ischemia (10 %) and venous thrombosis (10 %) among others [20]. In this case, femoral artery thrombosis was successfully treated with no other major complications. The duration of ECMO in reported cases was generally prolonged. This was also the case in this report, with a total duration of 26 days. Good outcomes have now been reported with the use of ECMO for more than 14 days for severe respiratory failure, with a survival up to 45 % [21]. This is lower than survival for short-time ECMO, but significantly higher than the reported in previous decades [21]. It is remarkable that this case took place in the middle of Covid-19 pandemic. Despite limited availability of pumps (because a great number of Covid-19 patients were on ECMO support) we decided to proceed given the good results on the published reports, which included a case of our own in 2012 [12].

In conclusion, the use of ECMO is an effective alternative for treatment of ARDS secondary to TB, the VAV modality being effective in patients who are also hemodynamically compromised; the use of ECMO for prolonged periods appears to be effective in these patients.

Author contribution

SB, AJM, PS, SBM and LGO all had made substantial contributions to the conception and design of the work. They all contributed to the acquisition, analysis and interpretation of the data. They all participated on the drafting, critical revision and final approval of the version to be published. They all agree to be accountable for all aspects of the work. Other Contributions: We sincerely thank Magdalena Méndez M.D. for the creation of the VAV-ECMO scheme.

Disclosures

The authors have nothing to disclose.

Funding

There was no funding.

Declaration of competing interest

None.

References

[1] R. Agarwal, D. Gupta, A.N. Aggarwal, D. Behera, S.K. Jindal, Experience with ARDS caused by tuberculosis in a respiratory intensive care unit, Intensive Care Med. Sep 31 (9) (2005) 1284–1287.

[2] S.E. Frick, C. Flothmann, B. Preiswerk, R. Behr, M. Genoni, Extracorporeal membrane oxygenation in miliary tuberculosis and aids: a case report, Thorac. Cardiovasc. Surg. Rep. 4 (1) (2015) 18–20.

[3] P.L. Lee, J.S. Jernt, Y.L. Chang, et al., Patient mortality of active pulmonary tuberculosis requiring mechanical ventilation, Eur Respir J. Jul 22 (1) (2003) 141–147.

[4] S.K. Sharma, A. Mohan, A. Banga, P.K. Saha, K.K. Guntupalli, Predictors of development and outcome in patients with acute respiratory distress syndrome due to tuberculosis, Int J Tuberc Lung Dis. Apr 10 (4) (2006) 429–435.

[5] V. Mutlu, S. Dhosaria, A.N. Aggarwal, D. Behera, I.S. Sehgal, R. Agarwal, Acute respiratory distress syndrome due to tuberculosis in a respiratory ICU over a 16-year period, Crit. Care Med. 45 (10) (2017) e1087–e1090.

[6] T. Pham, A. Combes, H. Roze, et al., Extracorporeal membrane oxygenation for pandemic influenza A(H1N1)-induced acute respiratory distress syndrome: a cohort study and propensity-matched analysis, Am J Respir Crit Care Med. Feb 187 (3) (2013) 276–285.

[7] A. Zangrillo, G. Biondi-Zoccai, G. Landoni, et al., Extracorporeal membrane oxygenation (ECMO) in patients with H1N1 influenza infection: a systematic review and meta-analysis including 8 studies and 266 patients receiving ECMO, Crit. Care 17 (1) (2013) R30.

[8] N. Omote, Y. Kondo, H. Taniguchi, et al., Acute respiratory distress syndrome due to severe pulmonary tuberculosis treated with extracorporeal membrane oxygenation: a case report and review of the literature, Respir Med Case Rep (2016) 31–33.

[9] T.M. Perillo, M.L. Heard, J.D. Fortenberry, J.A. Stockwell, M.K. Leonard Jr., Respiratory failure caused by tuberculous pneumonia requiring extracorporeal membrane oxygenation, Perfusion. Nov 16 (6) (2001) 525–529.

[10] E. Venteiindottir, G. Myrdal, K.O. Sverrisson, S.J. Skarphedinsdottir, G. Guðlaugsson, S. Karason, ARDS from miliary tuberculosis successfully treated with ECMO, Respir Med Case Rep (2019) 165–167.

[11] S.J. Nam, Y.J. Cho, The successful treatment of refractory respiratory failure due to miliary tuberculosis: survival after prolonged extracorporeal membrane oxygenation support, Clin Respir J. May 10 (3) (2016) 393–399.

[12] M. Andresen, P. Tapia, M. Mercado, G. Bugedo, S. Bravo, T. Reguera, Catastrophic respiratory failure from tuberculosis pneumonia: survival after prolonged extracorporeal membrane oxygenation support, Respir Med Case Rep (2013) 19–22.

[13] V. Cogliandro, G. Lapadula, A. Bandera, et al., ECMO: an alternative support for acute respiratory failure caused by tuberculosis? Int J Tuberc Lung Dis. Jul 18 (7) (2014) 879–881.

[14] N.G. Beinh, T. Manabe, D.X. Co, et al., Tuberculosis-induced acute respiratory distress syndrome treated with veno-venous extracorporeal membrane oxygenation, Respir Med Case Rep 28 (2019) 100900.

[15] S.I. Lee, H.J. Hwang, S.Y. Lee, et al., Veno-veno-arterial extracorporeal membrane oxygenation for acute respiratory distress syndrome with septic-induced cardiomyopathy due to severe pulmonary tuberculosis, J Artif Organs. Dec 20 (4) (2017) 359–364.

[16] W. Homan, E. Harman, N.M. Braun, C.P. Felton, T.K. King, J.P. Smith, Miliary tuberculosis presenting as acute respiratory failure: treatment by membrane oxygenator and ventricle pump, Chest. Mar 67 (3) (1975) 366–369.

[17] B. Monier, B. Fauroux, J.Y. Chevalier, et al., Miliary tuberculosis with acute respiratory failure and histiocytic hemophagocytosis. Successful treatment with extracorporeal lung support and epipodophyllotoxin VP 16-213, Acta Paediatr. Sep 81 (9) (1992) 725–727.

[18] T. Masri, G. Fotti, A. Zanella, et al., Long-term extracorporeal membrane oxygenation with minimal ventilatory support: a new paradigm for severe ARDS? Minerva Anestesiol. Mar 78 (3) (2012) 385–389.

[19] C. Contesto, A. Battisti, B. Agro, et al., A novel veno-arteriovenous extracorporeal membrane oxygenation with double pump for the treatment of Harlequin syndrome, Perfusion. May 35 (1 Suppl) (2020) 65–72.

[20] A. Zangrillo, G. Landoni, G. Biondi-Zoccai, et al., A meta-analysis of complications and mortality of extracorporeal membrane oxygenation, Crit Care Resusc. Sep 15 (3) (2013) 172–178.

[21] J. Podlanzy, F.T. Rycus, R.H. Bartlett, et al., Outcome of adult respiratory failure patients receiving prolonged (>14 Days) ECMO, Ann Surg. Mar 263 (3) (2016) 573–581.